Medications

Nasal spray approved for treating suicidal people

Johnson & Johnson's Spravato has been approved as the first antidepressant for actively suicidal people, as doctors are becoming increasingly concerned about COVID-19's effect on the mental health of Americans.

Psychology & Psychiatry

Hospital study examines the cost-effectiveness of esketamine

A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. Titled "Cost-Effectiveness of Esketamine Nasal ...

Oncology & Cancer

Revealed: How cancer develops resistance to treatment

Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment, a breakthrough study published in the journal Science has revealed. Bacteria use the same process, termed stress-induced mutagenesis, to ...

Psychology & Psychiatry

New study shows how ketamine combats depression

In low doses, the anaesthetic drug ketamine has been shown to have a rapid effect on difficult-to-treat depression. Researchers at Karolinska Institutet report that they have identified a key target for the drug: specific ...

page 2 from 25